bioMérieux: Good Q3 performance. Declining China leads to a shy upward revision in guidanceBUY, Fair Value EUR108 vs. EUR107 (+7%)
BioMérieux Q3 sales topped consensus by 5% standing at EUR478.3m, up 16.1% year on year (8.8%cc), driven by strong performances in both EMEA with southern Europe recovering and the Americas with BioFire’s momentum. FY2015 organic sales growth guidance is now expected at around 6.5% vs. in the 4.5%-6.5% range previously. EBIT guidance in maintained at EUR240-265m to reflect continuous investments to support the launch of new products.
For more information, please contact firstname.lastname@example.org